MGI Wins Company Innovation of the Year at 2022 Globee® Awards for Advanced COVID-19 Response Efforts

SHENZHEN, China, June 24, 2022 /PRNewswire/ — MGI, a company committed to being a world-leading life science innovator, has been awarded a Silver Globee® in the 14th Annual 2022 Golden Bridge Business and Innovation Awards® for its innovative COVID-19 pandemic control and response efforts worldwide. 

Since the rise of COVID-19, MGI has taken an active part in the prevention and control of the pandemic in over 70 countries and regions worldwide, including South Africa, Serbia, Saudi Arabia, the United Arab Emirates, Canada, and Australia.

From facilitating large-scale nucleic acid testing for the detection of the SARS-CoV-2 virus through providing MGI automation systems, to virus genome sequencing to inform the tracing and understanding of the epidemiology and virology of each variant, MGI’s DNBSEQ™ sequencers*, automation systems, and proprietary ATOPlex technology have been continuously put to work to combat the virus and keep communities safe. 

“MGI is honored to be recognized for our innovative technology* and inclusive approach towards tackling the pandemic by the Globee® Awards,” said Duncan Yu, President at MGI, “Through advanced genetic science and technology*, we are proud to support on the frontline of this important battle against COVID-19 and empower various countries and regions by supporting their genomic sequencing initiatives, enhancing their large-scale testing capability, and informing their pandemic response efforts.”

The coveted annual Golden Bridge Awards® are the world’s premier business awards program honoring global achievements in every major industry, with over 100 experts from around the world participating in the judging process. Fellow winners include IBM, KPMG, and Honeywell who have also been acknowledged for their business excellence and cutting-edge innovation.

Amidst the ongoing fight against COVID-19, MGI is committed to playing a key role in the detection, monitoring, surveillance, and tracing of COVID-19 and its variants to safeguard communities across the globe. It will continue to work relentlessly towards improving the efficiency, flexibility, and mobility of its core tools and technology* to meet ever-growing testing demands and to reach more people in need.

About MGI

MGI Tech Co. Ltd. (MGI), headquartered in Shenzhen, is committed to building core tools and technology to lead life science through intelligent innovation. Based on its proprietary technology, MGI focuses on research & development, production and sales of sequencing instruments, reagents, and related products to support life science research, agriculture, precision medicine and healthcare. MGI is a leading producer of clinical high-throughput gene sequencers*, and its multi-omics platforms include genetic sequencing*, medical imaging, and laboratory automation. MGI’s mission is to develop and promote advanced life science tools for future healthcare. For more information, please visit the MGI website or connect with us on Twitter, LinkedIn or YouTube.

*Unless otherwise informed, StandardMPS and CoolMPS sequencing reagents, and sequencers for use with such reagents are not available in Germany, USA, Spain, UK, China Hong Kong, Sweden, Belgium, Italy, Finland, Czech Republic, Switzerland, Portugal, Austria, and Romania.

Related posts:

MediLink Therapeutics Receives FDA Clearance of IND Application for YL201 Antibody Drug Conjugate Product AACR 2022: Ascentage Pharma Presents Latest Results from Six Preclinical Studies Ascletis Announces 3CLpro Inhibitor ASC11 Demonstrated Potential to be Effective Treatment for COVID-19 FDA Approves Direct Biologics to Proceed with a Landmark Phase 3 Acute Respiratory Distress Syndrome (ARDS) Trial

Author

GeneOnline